CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AbbVie Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AbbVie Inc
1 N Waukegan Rd
Phone: (847) 932-7900p:847 932-7900 NORTH CHICAGO, IL  60064  United States Ticker: ABBVABBV
Business Summary
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Richard A.Gonzalez 70 7/1/2024 1/2/2013
Chairman of the Board, Chief Executive Officer Robert A.Michael 53 7/1/2025 3/1/2017
Chief Financial Officer, Executive Vice President Scott T.Reents 56 11/28/2022 6/23/2022
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ABBVIE INC.
Actavis Capital S.a.r.l. Luxembourg
Allergan Pharmaceuticals Ireland Ireland
94 additional Subsidiary records available in full report.

Business Names
Business Name
0QCV
ABBV
AbbVie (Gibraltar) Holdings Limited
231 additional Business Names available in full report.

General Information
Number of Employees: 55,000 (As of 1/31/2025)
Outstanding Shares: 1,768,978,278 (As of 3/10/2025)
Shareholders: 56,544
Stock Exchange: NYSE
Federal Tax Id: 320375147
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 28, 2025